Clinical trials: IGA Glomerulonephritis
IgA Nephropathy
A Study of Probiotics in IgA Nephropathy
IgA nephropathy (IgAN) occurs when a specific form of the IgA antibody lodges on the kidneys and causes damage, which may lead to kidney failure. This form of IgA is likely to come from the gut and the upper airways.
- Trial name
- Pro-IgAN (NCT06767592)
- Testing
- Bio-Kult Advanced
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Leicester
IgA Nephropathy
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.
- Trial name
- NCT02052219
- Testing
- Blisibimod
- Sponsor
- Anthera Pharmaceuticals
Immunoglobulin A Nephropathy
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
- Trial name
- NCT07807995
- Testing
- Povetacicept
- Where
- 4 sites in United States
- Volunteers
- 605 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
IGA Nephropathy
Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy
A single-center random parallel study to compare the efficacy and safety of Mycophenolate mofetil versus intravenous Cyclophosphamide pulses in the treatment of crescentic IgA nephropathy
- Trial name
- NCT00301600
- Testing
- Mycophenolate mofetil
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanjing University School of Medicine
IgA Nephropathy
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).
- Trial name
- NCT03945318
- Testing
- BION-1301 Single Dose, BION-1301 Multiple Doses
- Where
- 16 sites in United States, South Korea and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject
The study is being conducted to Evaluate the Safety, Tolerability and Pharmacokinetics pharmacodynamics of SHR-2010 by intravenously/subcutaneously in Healthy Subject.
- Trial name
- NCT05398510
- Testing
- SHR-2010 injection
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Glomerulonephritis, IGA, Nephropathy, IGA
Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy
The purpose of this study is to test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.
- Conditions
- Glomerulonephritis, IGA, Nephropathy, IGA, IGA Nephropathy
- Trial name
- SIREPNA (NCT00396721)
- Testing
- ACE inhibitor + statin, Sirolimus (study drug)+ACE inhibitor + statin
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Josep m Cruzado